Daily Stock Analysis, IMDZ, Immune Design Corp, priceseries

Immune Design Corp. Daily Stock Analysis
Stock Information
Open
1.46
Close
1.46
High
1.51
Low
1.45
Previous Close
1.49
Daily Price Gain
-0.03
YTD High
1.70
YTD High Date
Jan 7, 2019
YTD Low
1.22
YTD Low Date
Jan 3, 2019
YTD Price Change
0.13
YTD Gain
9.77%
52 Week High
5.05
52 Week High Date
Jul 6, 2018
52 Week Low
1.10
52 Week Low Date
Dec 24, 2018
52 Week Price Change
-1.99
52 Week Gain
-57.68%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 9. 2017
5.90
Mar 24. 2017
6.48
11 Trading Days
9.86%
Link
LONG
May 18. 2017
6.70
May 31. 2017
7.23
8 Trading Days
7.84%
Link
LONG
Jun 15. 2017
7.15
Jul 5. 2017
9.29
13 Trading Days
29.89%
Link
LONG
Jul 21. 2017
9.95
Jul 31. 2017
10.45
6 Trading Days
5.03%
Link
LONG
May 9. 2018
3.75
Jun 4. 2018
4.35
17 Trading Days
15.89%
Link
LONG
Nov 29. 2018
1.48
Dec 13. 2018
1.71
9 Trading Days
15.41%
Link
Company Information
Stock Symbol
IMDZ
Exchange
NasdaqGM
Company URL
http://www.immunedesign.com
Company Phone
(206) 682-0645
CEO
Carlos V. Paya
Headquarters
Washington
Business Address
1616 EASTLAKE AVE. E, SUITE 310, SEATTLE, WA 98102
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001437786
About

Immune Design Corp. is a clinical-stage immunotherapy company, which focuses on cancer with next-generation in vivo approaches designed to enable the body's immune system to fight disease. It includes products candidates from discovery platforms, IMDZVe or ZVex, and GLAAS. The company was founded by Steven G. Reed and David Baltimore on February 20, 2008 and is headquartered in Seattle, WA.

Description

Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo immunotherapy treatments. It develops various product candidates based on its ZVex and GLAAS product discovery platforms. The company's products include CMB305, which is in Phase 2 trial for the treatment of NY-ESO-1 tumor antigen; LV305 that is in Phase 1 trial for the treatment of patients with relapsed or metastatic melanoma, sarcoma, ovarian cancer, or non-small cell lung cancer that express NY-ESO-1; and G100, an intratumoral immune activation product candidate for the treatment of patients with Merkel cell carcinoma and non-Hodgkin Lymphoma. In addition, its technologies are also used in the fields of infectious diseases and allergies. The company has license agreements with California Institute of Technology, University of North Carolina at Chapel Hill, Infectious Disease Research Institute, MedImmune LLC, and Sanofi; a collaboration agreement with Sanofi Pasteur; and a clinical collaboration with Gritstone Oncology. Immune Design Corp. was founded in 2008 and is headquartered in Seattle, Washington.